Cambrian Biopharma is the largest investor in cancer immunotherapy developer Sensei Biotherapeutics, which has filed to raise up to $100m.

Novo and existing backer GV participated in a round that lifted the heart disease drug developer's overall funding to more than $215m.

University of Washington spinout AltPep will use the proceeds from the Alexandria Venture Investments-backed round to advance a lead asset targeting Alzheimer’s disease.

Biohaven has purchased the 58% stake cancer immunotherapy developer Kleo Pharmaceuticals it did not already own.

The Anthem and Comcast-backed remote healthcare provider doubled its valuation for the second time in 10 months, in a series E round valuing it at $1.5bn.

HealthQuest Capital supplied $75m for the medical test provider, which counts The Chernin Group as an investor, at a flat $1.3bn valuation.

UPMC-backed cancer immunotherapy developer BlueSphere Bio has attracted an initial $45.6m in series B funding towards a $105m target for its close.

Fidelity provided a $4.8m second tranche after a first close featuring vehicles for Kyushu University and Osaka University.

Pitt spinout BlueSphere Bio has attracted an initial $45.6m in series B funding towards a $105m target size.

Existing shareholder Biohaven has agreed to purchase the remaining stake in Kleo Pharmaceuticals, a Yale spinout it first backed in 2016.